AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7865687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin 50 anti-factor Xa IU/kg i.v. with PS 1 mg/100 IU of heparin
Number of subjects: 50
Study 7865687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin 75 anti-factor Xa IU/kg s.c. with PS 1 mg/100 IU of heparin
Number of subjects: 50
Study 7865687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 anti-factor Xa IU/kg s.c. with PS 1 mg/100 IU of heparin
Number of subjects: 50
Study 7865687 — intervention group
Group type: COMPARATOR
Intervention: Saline s.c. with PS 0.5 mg/kg
Number of subjects: 50
Study 2764689 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice (experimental group)
Number of subjects: 20
Study 2764689 — intervention group
Group type: COMPARATOR
Intervention: Control (no practice)
Number of subjects: 20
Study 2764689 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice 1 (experimental group)
Number of subjects: 20
Study 318795 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 20 mg
Number of subjects: 25
Study 318795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31238591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care group (n = 33)
Number of subjects: 66
Study 31238591 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 66
Study 28844990 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaco-invasive strategy with half-dose alteplase
Number of subjects: 344
Study 28844990 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 344
Study 25577042 — intervention group
Group type: EXPERIMENTAL
Intervention: SMV plus pegylated interferon and ribavirin (SMV/PegIFN/R)
Number of subjects: 731
Study 25577042 — intervention group
Group type: COMPARATOR
Intervention: PegIFN/R
Number of subjects: 731
Study 23761205 — intervention group
Group type: EXPERIMENTAL
Intervention: W‐RENA (Internet-based maintenance treatment)
Number of subjects: 400
Study 23761205 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 400
Study 21895504 — intervention group
Group type: COMPARATOR
Intervention: Cemented Charnley flanged 40 femoral stem (n = 30)
Number of subjects: 150
Study 21895504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented Spectron EF femoral stem (n = 120)
Number of subjects: 150
Study 18784350 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-session theory-based intervention
Number of subjects: 212
Study 18784350 — intervention group
Group type: COMPARATOR
Intervention: 1-session standard of care comparison condition
Number of subjects: 212
Study 18784350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 212
Study 17085994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg tid PO
Number of subjects: 61
Study 17085994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 15485403 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based antihypertensive therapy
Number of subjects: 0
Study 15485403 — intervention group
Group type: COMPARATOR
Intervention: Placebo-based conventional antihypertensive therapy
Number of subjects: 0
Study 11487451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (conjugated estrogen with progestin)
Number of subjects: 0
Study 11487451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9271771 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupressure
Number of subjects: 31
Study 8204123 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated tissue plasminogen activator (t-PA) and intravenous heparin
Number of subjects: 41021
Study 8204123 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase and subcutaneous heparin
Number of subjects: 41021
Study 8204123 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase and intravenous heparin
Number of subjects: 41021
Study 8204123 — intervention group
Group type: COMPARATOR
Intervention: Combination of streptokinase plus t-PA with intravenous heparin
Number of subjects: 41021
Study 8204123 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated t-PA
Number of subjects: 41021
Study 8204123 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination strategy
Number of subjects: 41021
Study 3732715 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (360 mg daily)
Number of subjects: 13
Study 3732715 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg daily)
Number of subjects: 13
Study 3732715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29669938 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (300 mg/d)
Number of subjects: 25
Study 29669938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 26177984 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation and PRS voting
Number of subjects: 35
Study 26177984 — intervention group
Group type: COMPARATOR
Intervention: Case-based discussion (Control)
Number of subjects: 35
Study 24172724 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympic weightlifting (OWL)
Number of subjects: 63
Study 24172724 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 63
Study 24172724 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional resistance training (RT)
Number of subjects: 63
Study 24172724 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 23011661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemin plus trypsin
Number of subjects: 28
Study 23011661 — intervention group
Group type: COMPARATOR
Intervention: Hemin
Number of subjects: 28
Study 23011661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin plus trypsin
Number of subjects: 28
Study 23011661 — intervention group
Group type: COMPARATOR
Intervention: Hemoglobin
Number of subjects: 28
Study 23011661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb plus mucin plus trypsin
Number of subjects: 28
Study 23011661 — intervention group
Group type: COMPARATOR
Intervention: Hemin plus mucin
Number of subjects: 28
Study 23011661 — intervention group
Group type: COMPARATOR
Intervention: Hb plus mucin
Number of subjects: 28
Study 20964256 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA)
Number of subjects: 147
Study 20964256 — intervention group
Group type: EXPERIMENTAL
Intervention: Streitberger needle (SN)
Number of subjects: 147
Study 19065553 — intervention group
Group type: EXPERIMENTAL
Intervention: 1319 nm diode laser (Sciton, Palo Alto, CA)
Number of subjects: 24
Study 19065553 — intervention group
Group type: EXPERIMENTAL
Intervention: 940 nm diode laser (Dornier, Kennasaw, GA)
Number of subjects: 24
Study 16002074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg
Number of subjects: 76
Study 16002074 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP-H5
Number of subjects: 76
Study 16002074 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR1-h10
Number of subjects: 76
Study 16002074 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP-H13 and MDR1-h4
Number of subjects: 76
Study 16002074 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP-H5 and MDR1-h10
Number of subjects: 76
Study 12675716 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood
Number of subjects: 33
Study 12675716 — intervention group
Group type: COMPARATOR
Intervention: RBCs and FFP
Number of subjects: 33
Study 10774784 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (pravastatin or simvastatin)
Number of subjects: 41
Study 10774784 — intervention group
Group type: COMPARATOR
Intervention: Dietary treatment alone (matched controls with high cholesterol)
Number of subjects: 41
Study 10774784 — intervention group
Group type: COMPARATOR
Intervention: Dietary treatment alone (matched controls with normal cholesterol)
Number of subjects: 41
Study 8863775 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma method (PRP-PCs)
Number of subjects: 64
Study 8863775 — intervention group
Group type: COMPARATOR
Intervention: Buffy coat method (BC-PCs)
Number of subjects: 64
Study 1736002 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion flow rate at 1.75 L.min‐1.m‐2
Number of subjects: 0
Study 1736002 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion flow rate at 2.25 L.min‐1.m‐2
Number of subjects: 0
Study 1736002 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-stat method
Number of subjects: 0
Study 1736002 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat method
Number of subjects: 0
Study 6669631 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 0
Study 6669631 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 0
Study 6669631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6669631 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 3.75 mg
Number of subjects: 0
Study 6669631 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 11.25 mg
Number of subjects: 0
Study 30730957 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA treatment
Number of subjects: 628
Study 30730957 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 628
Study 30282686 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at high-sensitised points
Number of subjects: 666
Study 30282686 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at low/non-sensitised points
Number of subjects: 666
Study 30282686 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (standard acupuncture treatment after the study)
Number of subjects: 666
Study 27100101 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 supplementation (90 μg) and cholecalciferol (10 μg)
Number of subjects: 38
Study 27100101 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol (10 μg) alone
Number of subjects: 38
Study 27100101 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 supplementation
Number of subjects: 38
Study 25285539 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir, 300 mg/d, with ritonavir, 100 mg/d
Number of subjects: 1809
Study 25285539 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir, 400 mg twice daily
Number of subjects: 1809
Study 25285539 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir, 800 mg/d, with ritonavir, 100 mg/d
Number of subjects: 1809
Study 25285539 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcomes of all regimens
Number of subjects: 1809
Study 25285539 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir
Number of subjects: 1809
Study 25285539 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir
Number of subjects: 1809
Study 22918156 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily for 24 weeks
Number of subjects: 56
Study 22918156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 20484942 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meals with predominantly meat
Number of subjects: 12
Study 20484942 — intervention group
Group type: COMPARATOR
Intervention: High-protein meals with predominantly dairy
Number of subjects: 12
Study 20484942 — intervention group
Group type: COMPARATOR
Intervention: High-protein meals with predominantly soy
Number of subjects: 12
Study 17388711 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (8-24 mg)
Number of subjects: 35
Study 17388711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 16143381 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching with 37% carbamide peroxide + at-home bleaching with 10% carbamide peroxide (G1)
Number of subjects: 44
Study 16143381 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching with 37% carbamide peroxide + at-home placebo (G2)
Number of subjects: 44
Study 16143381 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office placebo + at-home bleaching with 10% carbamide peroxide (G3)
Number of subjects: 44
Study 16143381 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office placebo + at-home placebo (G4)
Number of subjects: 44
Study 12378396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunar stents (12 and 16 mm long, iridium-oxide coated)
Number of subjects: 87
Study 10475387 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients classified as asymptomatic with mild CNS symptoms
Number of subjects: 685
Study 10475387 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients classified as asymptomatic with minimal symptoms
Number of subjects: 685
Study 10475387 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients classified as asymptomatic with more than minimal symptoms
Number of subjects: 685
Study 10475387 — intervention group
Group type: COMPARATOR
Intervention: Patients without any symptoms
Number of subjects: 685
Study 10475387 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild symptoms
Number of subjects: 685
Study 7549379 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus (AM) oral liquor combined with routine therapy
Number of subjects: 0
Study 7549379 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy alone
Number of subjects: 0
Study 2149726 — intervention group
Group type: EXPERIMENTAL
Intervention: White light (photon density of 2.3 X 10(15) photons/s/cm2)
Number of subjects: 18
Study 2149726 — intervention group
Group type: COMPARATOR
Intervention: Red light
Number of subjects: 18
Study 2149726 — intervention group
Group type: COMPARATOR
Intervention: Blue light
Number of subjects: 18
Study 7023494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluproquazone (100 mg)
Number of subjects: 123
Study 7023494 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (500 mg)
Number of subjects: 123
Study 30853317 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix
Number of subjects: 160
Study 30853317 — intervention group
Group type: EXPERIMENTAL
Intervention: AT LISA tri 839MP
Number of subjects: 160
Study 30853317 — intervention group
Group type: EXPERIMENTAL
Intervention: FineVision
Number of subjects: 160
Study 30853317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis ZLB00
Number of subjects: 160
Study 30853317 — intervention group
Group type: COMPARATOR
Intervention: Bifocal IOL
Number of subjects: 160
Study 30096657 — intervention group
Group type: EXPERIMENTAL
Intervention: High-difficulty C‐FiTT with withdrawal content
Number of subjects: 550
Study 30096657 — intervention group
Group type: EXPERIMENTAL
Intervention: High-difficulty C‐FiTT
Number of subjects: 550
Study 30096657 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-difficulty C‐FiTT
Number of subjects: 550
Study 30096657 — intervention group
Group type: COMPARATOR
Intervention: Neutral control group
Number of subjects: 550
Study 26995369 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitive cardiac troponin T (hs-cTnT) levels
Number of subjects: 1133
Study 26995369 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT levels <3 ng/L
Number of subjects: 1133
Study 26995369 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT levels 3-14 ng/L
Number of subjects: 1133
Study 26995369 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT levels ≥14 ng/L
Number of subjects: 1133
Study 26995369 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude model of hs-cTnT
Number of subjects: 1133
Study 24033567 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut supplement diet (75 g per day)
Number of subjects: 19
Study 24033567 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 19
Study 22061077 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride (2-4 mg daily)
Number of subjects: 7
Study 22061077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 19189878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 186
Study 19189878 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 186
Study 17452896 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (12-week program) in RTx patients
Number of subjects: 72
Study 17452896 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (12-week program) in HD patients
Number of subjects: 72
Study 17452896 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (12-week program) in healthy controls
Number of subjects: 72
Study 17452896 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 72
Study 15548969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine withdrawal after 3 months of treatment with sirolimus
Number of subjects: 64
Study 15548969 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine continued after 3 months of treatment with sirolimus
Number of subjects: 64
Study 11578152 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily)
Number of subjects: 2253
Study 11578152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2253
Study 9758084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillometric blood pressure measuring device (Visomat OZ D2 International)
Number of subjects: 407
Study 9758084 — intervention group
Group type: COMPARATOR
Intervention: Standard sphygmomanometer
Number of subjects: 407
Study 7886177 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-choice randomized-response technique
Number of subjects: 352
Study 7886177 — intervention group
Group type: COMPARATOR
Intervention: Direct-inquiry techniques
Number of subjects: 352
Study 2954078 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 45
Study 2954078 — intervention group
Group type: COMPARATOR
Intervention: Control (no prednisolone)
Number of subjects: 45
Study 29729555 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Number of subjects: 122
Study 29729555 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation and Supportive Therapy (PST)
Number of subjects: 122
Study 27172286 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge-shaped resection of the cranial portion of the posterior bony arch during ODLP (group A)
Number of subjects: 75
Study 27172286 — intervention group
Group type: COMPARATOR
Intervention: ODLP alone (group B)
Number of subjects: 75
Study 25303337 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal paracetamol use
Number of subjects: 120
Study 25303337 — intervention group
Group type: COMPARATOR
Intervention: Restricted paracetamol use
Number of subjects: 120
Study 23635737 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic midurethral sling
Number of subjects: 597
Study 23635737 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator midurethral sling
Number of subjects: 597
Study 23635737 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment success
Number of subjects: 597
Study 23635737 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in Urogenital Distress Inventory scores
Number of subjects: 597
Study 23635737 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in Incontinence Impact Questionnaire scores
Number of subjects: 597
Study 23635737 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer complications
Number of subjects: 597
Study 21623248 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubular diskectomy
Number of subjects: 325
Study 21623248 — intervention group
Group type: COMPARATOR
Intervention: Conventional microdiskectomy
Number of subjects: 325
Study 18078862 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 1495
Study 18078862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1495
Study 12624674 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.5 M)
Number of subjects: 5
Study 12624674 — intervention group
Group type: COMPARATOR
Intervention: Gadobutrol (1.0 M)
Number of subjects: 5
Study 12624674 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.5 M)
Number of subjects: 5
Study 10438389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin, twice daily for 5 days
Number of subjects: 76
Study 10438389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 7551950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin given daily with radiotherapy
Number of subjects: 170
Study 7551950 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality arms (cisplatin with carboplatin)
Number of subjects: 170
Study 7551950 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy arms
Number of subjects: 170
Study 7551950 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin, carboplatin, 5‐fluorouracil, mitomycin‐C
Number of subjects: 170
Study 2350528 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg
Number of subjects: 12
Study 2350528 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg alone
Number of subjects: 12
Study 385261 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxyferriscorbone
Number of subjects: 46
Study 385261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 46
Study 31762342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) based pain education
Number of subjects: 60
Study 31762342 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 30649903 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary ACLR
Number of subjects: 675
Study 30649903 — intervention group
Group type: EXPERIMENTAL
Intervention: First ACLR
Number of subjects: 675
Study 30649903 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision ACLR
Number of subjects: 675
Study 30649903 — intervention group
Group type: EXPERIMENTAL
Intervention: Second primary ACLR
Number of subjects: 675
Study 30649903 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 675
Study 30649903 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 675
Study 30649903 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with previous ACLR
Number of subjects: 675